Karyopharm Therapeutics | KPTI - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
AbbVie USD 5.57B 2.9B 2026-03
Abbott USD 2.39B 27M 2026-03
Amgen USD 1.51B 2.41B 2025-12
AstraZeneca USD 3.91B 1.28B 2026-03
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Incyte USD 343.6M 46.34M 2026-03
J&J USD 7.82B 2.86B 2026-03
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
MacroGenics USD -14.93M 31.75M 2025-12
Merck USD 3.42B 3.32B 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Novartis USD 3.84B 802M 2026-03
Novartis USD 5.17B 637M 2025-09
Pfizer USD -1.64B 4.98B 2025-12
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Takeda JPY 133.86B 105.69B 2025-12
Tectonic Therapeutic USD -18.97M 63K 2025-12
TG Therapeutics USD 45.09M 19.18M 2025-12
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Xencor USD -4.27M 1.76M 2025-12